Key result
~93% of specialists choose LMWH for initial cancer-associated thrombosis, while DOAC use depends on cancer site.
Why the study?
Specialists managing cancer-associated thrombosis must decide between LMWHs and DOACs, but prescribing practices and determinants are not well characterized.
Cross-Sectional (n=376)
In French clinical practice, LMWHs remain the preferred initial treatment for cancer-associated thrombosis, while DOAC use is largely driven by cancer site and anticancer treatments.
Answers are grounded in this paper and cite their sources.
Survey of vascular specialists reveals CAT anticoagulant practice variation; leaves open optimal DOAC vs LMWH selection in cancer.
Low molecular weight heparins (LMWHs) are recommended by international guidelines for at least 6 months in patients with cancer-associated thromboembolism (CAT). Direct oral anticoagulants (DOACs) have been proposed as an alternative to LMWH. In clinical practice, the specialists in charge of CAT have to decide which anticoagulant to prescribe. An electronic survey tool, including vignettes and questions, was sent to members of the French Society of Vascular Medicine, the French-speaking association for supportive care in oncology and the Investigation Network On Venous Thrombo-Embolism. Among the 376 respondents, LMWHs were reported as the first choice by most specialists. The prescription of DOACs within the first 3 weeks of CAT diagnosis was highly dependent on the cancer site: 5.9%, 18.6% and 24.5% in patients with locally advanced colorectal, lung and breast cancer, respectively. The determinants were mostly related to cancer (site and stage or evolution) and to anticancer treatments. For 61% of physicians, some anticancer treatments were contraindications to DOACs. However, almost 90% of physicians considered switching to DOAC after a median 3-month period of LMWHs. In daily practice, LMWHs and DOACs are now considered by specialists of CAT; the decision is mostly driven by the site of cancer. The role of anticancer treatments in the decision remains to be investigated.
No takes yet. Share an insight, caveat, or question.
Mahé et al. (2022) conducted a cross-sectional in Cancer-associated thrombosis (n=376). Survey on anticoagulant treatment preferences was evaluated on Proportion of specialists choosing LMWH as first-line treatment for initial CAT (95% CI 90.2-95.4). Low molecular weight heparins were reported as the first-choice initial treatment for cancer-associated thrombosis by 92.8% of specialists, with DOAC prescription highly dependent on cancer site.
Synapse has enriched 10 related papers. Consider them for comparative context: